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Abstract	
		
Objectives:	Physiological	replacement	is	important	for	optimal	control	of	congenital	
adrenal	hyperplasia	(CAH).	We	examined	glucocorticoid	and	mineralocorticoid	
replacement	in	children	and	adults	with	CAH.		
	
Methods:	Data	were	extracted	in	February	2017	for	22	centres	in	14	countries	from	
the	international	I-CAH	registry	(www.i-cah.org).	1501	events	from	269	patients	seen	
between	1987	and	2017	were	analyzed.		
	
Results:	256	patients	had	information	on	glucocorticoids	(F	136,	M	116,	4	sex	not	
assigned;	0-1y	n=130,	69F,	1-8y	n=153	82F,	8-12y	n=42	26F,	12-18y	n=39	23F,	18-30y	
n=27	12F,	30-60y	n=26	14F).	The	majority	of	pediatric	patients	were	treated	with	
hydrocortisone	(HC)	and	adults	with	prednisolone	(Pred)	and	some	with	cortisone	
acetate	(CA)	and	dexamethasone	(DEX);	0-1y:	HC	92%,	CA	8%,	Dex	1%,	1-8y:	HC	93%,	
CA	6%,	Pred	1%,	8-12y:	HC	83%,	CA	7%,	Dex	5%,	Pred	5%,	12-18y:	HC	69%,	CA	3%,	
Dex	18%,	Pred	10%,	18-30y:	HC	33%,	CA	4%,	Dex	26%,	Pred	37%,	30-60y:	HC	31%,	
Dex	12%,	Pred	54%.	The	HC-equivalent	dose	varied	significantly	between	age	groups,	
p=0.02	(mean±sd	in	mg/m2/day);	0-1y	(15.3±8.3),	1-8y	(13.6±12.3),	8-12y	(15.2±5.9),	
12-18y	(15.7±6.8),	18-30y	(16.0±5.1),	30-60y	(12.2±5.8).	Information	on	
mineralocorticoids	was	available	in	22We	hab7	patients	(F	119,	M	105,	3	sex	not	
assigned).	Average	fludrocortisone	dose	and	frequency	of	administration	was	
(mean±sd,	frequency	in	%	of	patients);	0-1y	(101.2±62.1mcg,	od	59%/	bd	32%/	tds	
11%,),	1-8y	(91.07±61.7mcg,	od	70%/	bd	26%/	tds	4%),	8-12y	(84.41±44.1mcg,	od	
82%/	bd	32%/	tds	3%),	12-18y	(111.4±-52.6mcg,	od	81%/	bd	19%),	18-30y	
(134.5±68.2mcg,	od	90%/	bd	10%),	30-60y	(152.9±74.4mcg,	od	71%/	bd	29%).	Total	
fludrocortisone	dose	mcg/m2/day	was	significantly	higher	in	children	younger	than	
8y,	p<0.0001	(mean±sd):	0-1y	(274.2±181.7),	1-8y	(146.7±129.7),	8-12y	(63.3±34.3),	
12-18y	(66.43±34.3),	18-30y	(77.1±37.1),	30-60y	(74.8±37.9).	
	
Conclusions:	Data	from	a	large	international	cohort	of	CAH	patients	confirm	
variations	in	the	hormonal	replacement	regimens	between	pediatric	and	adult	
patients.	Glucocorticoid	doses	were	high	in	some	age	groups	compared	to	
recommendations	in	current	guidelines.		
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